Amyris Inc. (NASDAQ:AMRS)‘s stock had its “buy” rating restated by stock analysts at Singular Research in a research note issued to investors on Wednesday. They presently have a $2.80 price objective on the stock. Singular Research’s target price would suggest a potential upside of 429.40% from the company’s current price.
Separately, Zacks Investment Research upgraded shares of Amyris from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a report on Tuesday, August 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $2.66.
Amyris (NASDAQ:AMRS) traded up 7.1081% during mid-day trading on Wednesday, reaching $0.5289. 1,978,006 shares of the company traded hands. The firm’s market capitalization is $124.30 million. Amyris has a 52 week low of $0.31 and a 52 week high of $2.57. The stock’s 50 day moving average price is $0.44 and its 200 day moving average price is $0.64.
Amyris (NASDAQ:AMRS) last issued its earnings results on Thursday, August 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. The company earned $9.60 million during the quarter, compared to analyst estimates of $15.23 million. During the same quarter in the previous year, the company posted ($0.47) EPS. The company’s quarterly revenue was up 23.1% on a year-over-year basis. Equities analysts forecast that Amyris will post ($0.20) EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Amyris during the first quarter worth approximately $269,000. Finally, Vanguard Group Inc. increased its position in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares in the last quarter. Hedge funds and other institutional investors own 35.68% of the company’s stock.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.